Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

We were getting there.” A pharmacist holds a vial of lenacapavir, an injectable drug to treat HIV, at the Desmond Tutu Health Foundation’s Masiphumelele Research Site, in Cape Town ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Lenacapavir for HIV prevention remains investigational and is not approved anywhere globally. Phase 1 studies indicate promising results for once-yearly use. However, further research, including ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...